editor
ebola
viru
current
caus
unpreced
outbreak
west
africa
pathogen
classifi
biosafeti
level
pathogen
handl
highlevel
biosafeti
set
viru
neutral
consid
gold
standard
serolog
assay
infect
case
ebola
test
requir
cultur
live
viru
facil
stringent
biosafeti
requir
option
clinic
diagnosi
epidemiolog
studi
ebola
case
limit
reason
develop
pseudovir
particl
neutral
ppnt
assay
detect
neutral
antibodi
ebola
viru
contain
ebola
glycoprotein
gp
major
target
neutral
antibodi
human
pseudovir
particl
gener
studi
lentivir
vector
carri
gp
zair
ebolaviru
detect
current
outbreak
method
pseudovir
particl
product
ppnt
assay
essenti
ident
middl
east
respiratori
syndrom
mer
influenza
previous
describ
briefli
codonoptim
gp
sequenc
chemic
synthes
genscript
subclon
proteinexpress
vector
result
pseudovir
particl
capabl
achiev
singleround
infect
contain
luciferas
report
gene
express
infect
cell
antigp
neutral
antibodi
inhibit
entri
pseudovir
particl
cell
therebi
inhibit
express
luciferas
assay
ebola
pseudovir
particl
product
prepar
titrat
dilut
level
could
produc
countss
posit
infect
control
reaction
luciferas
assay
steadyglo
luciferas
assay
system
promega
contrast
mockinfect
cell
ie
cell
treat
absenc
pseudovir
particl
yield
background
signal
assay
posit
infect
control
tabl
typic
ppnt
assay
serolog
screen
heattreat
serum
sampl
min
incub
dilut
pseudoparticl
reaction
min
inocul
onto
vero
cell
luciferas
activ
infect
cell
examin
h
postinfect
base
previou
experi
similar
assay
cutoff
valu
posit
reaction
set
valu
deduc
posit
infect
control
see
determin
neutral
antibodi
titer
serum
sampl
serial
dilut
sampl
specimen
start
dilut
use
ppnt
assay
thu
sampl
neutral
antibodi
titer
consid
posit
specimen
determin
whether
ppnt
assay
reactiv
ebola
viru
test
neutral
monoclon
antibodi
specif
z
ebolaviru
gp
antibodi
could
neutral
pseudovir
particl
dosedepend
manner
tabl
also
evalu
test
use
serum
sampl
collect
human
anim
tabl
serum
sampl
test
screen
dilut
part
part
neg
assay
ie
valu
deduc
posit
infect
control
studi
human
sampl
collect
healthi
individu
hong
kong
ebola
case
report
histori
addit
studi
anim
speci
known
suscept
host
ebola
virus
overal
result
suggest
ppnt
assay
specif
neutral
antibodi
ebola
viru
studi
limit
evalu
assay
need
particular
abl
use
ebola
neutral
monoclon
antibodi
neg
humananim
serum
sampl
evalu
studi
monoclon
antibodi
target
differ
conserv
region
z
ebolaviru
gp
one
antibodi
known
bind
conform
epitop
z
ebolaviru
gp
indic
gp
pseudovir
particl
correctli
fold
abl
obtain
convalesc
sera
ebola
patient
evalu
assay
howev
convalesc
human
serum
sampl
difficult
obtain
limit
avail
legal
issu
biosafeti
concern
nonetheless
import
evalu
assay
futur
use
convalesc
sera
known
igg
igmposit
ebola
viru
assay
potenti
applic
studi
relat
seroepidemiolog
passiv
immunotherapi
vaccin
immunogen
avoid
laboratoryacquir
infect
emphas
serum
sampl
confirm
suspect
case
must
fulli
inactiv
downstream
process
